Ann: PromarkerD US commercialisation & Promarker pipeline update, page-42

Appreciate giving another perspective. I feel PromarkerD is already the gold standard for diagnosing DKD. Also, the company has many other novel tests which will provide advocacy for many who have undiagnosed illnesses, and this is important for investors because PromarkerD is just the first of many tests, what could end up being an avalanche of royalties in the not-too-distant future for this company.

The announcement wasn't, in my view, worded in the right way and it's not the first time I've felt Richard hasn't provided this to investors. He should've highlighted that the roll out is more complex, for Sonic, and that with an expected high take-up from GP's it would be inexcusable to not have enough pathology centres with the ability to produce the results in a timely fashion. So, because of this, there was plenty who bought in recently that thought this test may not reach the market, which is preposterous.

Time will tell which one of us is right, but as an investor, who understands these types of plays always take longer to come to fruition, I am quietly confident within this calendar year we'll start seeing royalties from this test.